​CBRE Global Investors is targeting EUR8.3 billion of transactions in EMEA in 2016.

The company continues to have a strong focus on  new investments this year, targeting EUR5.3 billion of acquisitions throughout Europe, as it looks to invest increased real estate allocations from existing and new clients. In addition it will be looking to sell EUR3 billion of assets from end-of-term programmes and capitalise on opportunities to harvest gains where appropriate.

“Our clients continue to put faith in our ability to find attractive risk weighted opportunities, actively manage their assets and create value through the cycle,” said Sophie van Oosterom, CIO EMEA.

“We are closely watching market events globally and currently still see good levels of liquidity;  the continued gap with bond yields means the case for property remains attractive. Our investment programmes will continue to be based on input from our strong research teams and our team of local on-the-ground experts.”

Retail will again be a major focus with current requirements of around EUR2.4 billion, underscoring the company’s market leading position in the sector. In 2015, around 60% of its acquisitions were in retail and the company currently has approximately EUR14.7 billion of assets under management in that segment of the market. The company investment interest also includes significant dry powder for logistics (EUR 1.6bn) and offices (EUR 1.0bn) respectively.

“We have a wide range of requirements and our experienced local transaction teams are focused to find the best possible deals for our clients. We completed over 200 transactions last year in EMEA and have a well-earned reputation for executing the deals we agree. We have a strong pipeline of deals currently under offer and continue to source new opportunities across our EMEA platform.” said John Mulqueen, Head of Transactions EMEA.

For disposals, the company continues to undertake an orderly sale of assets from end-of-term programmes and capitalise on opportunities to harvest gains where appropriate.